# Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Source: https://onco.cc/trials/nct06047379/  
OnCo record `nct06047379` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Ipilimumab, Pembrolizumab, Nivolumab in cervical cancer and colorectal cancer, run by Neonc Technologies, Inc., now recruiting.

## Summary

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis is a phase 1/2 interventional study registered as NCT06047379 by Neonc Technologies, Inc., with 134 participants planned, started 2023-11-01 and due to reach its primary completion in 2027-02-28. Interventions recorded: NEO212 Oral Capsule, Ipilimumab, Pembrolizumab, Nivolumab, Regorafenib. Conditions listed: Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06047379
- Phase: 1/2
- Setting: An Open-label Phase 1/2 Dose Finding, Safety and Efficacy Study of Oral NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Uncontrolled Brain Metastasis in Patients With Select Solid Tumors.
- Sponsor: Neonc Technologies, Inc.
- Enrolled: 134

## Sources

- ClinicalTrials.gov NCT06047379: https://clinicaltrials.gov/study/NCT06047379

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Melanoma](https://onco.cc/cancers/melanoma/), [Merkel cell carcinoma](https://onco.cc/cancers/merkel-cell-carcinoma/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Ipilimumab](https://onco.cc/drugs/ipilimumab/), [Nivolumab](https://onco.cc/drugs/nivolumab/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Regorafenib](https://onco.cc/drugs/regorafenib/)
- companies: [Neonc Technologies](https://onco.cc/companies/neonc-technologies/)

---
JSON: https://onco.cc/api/v1/entities/nct06047379.json